CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan · Delayed Price · Currency is TWD 92.40
+1.30 (1.43%)
Aug 19, 2026, 10:55 AM CST
CH Biotech R&D Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,874 | 1,819 | 1,636 | 1,515 | 1,434 | 1,019 | |
Revenue Growth | 11.26% | 11.21% | 7.98% | 5.63% | 40.81% | 45.05% |
Cost of Revenue | 297.23 | 292.36 | 270.92 | 254.73 | 299.52 | 170.56 |
Gross Profit | 1,577 | 1,527 | 1,365 | 1,260 | 1,135 | 847.95 |
Selling, General & Admin | 472.81 | 485.79 | 459.16 | 389 | 351.12 | 267.2 |
Research & Development | 421.35 | 406.72 | 363.36 | 305.24 | 272.41 | 221.48 |
Operating Expenses | 894.92 | 903.69 | 822.52 | 694.24 | 623.54 | 488.68 |
Operating Income | 681.83 | 623.13 | 542.3 | 565.86 | 511.06 | 359.27 |
Interest Expense | -16.15 | -16.96 | -15 | -16.81 | -16.81 | -13.9 |
Interest & Investment Income | 12.17 | 11.33 | 18.8 | 17.22 | 5.12 | 0.6 |
Earnings From Equity Investments | -1.45 | -3.1 | -0.26 | -0.05 | - | - |
Currency Exchange Gain (Loss) | 54.26 | -50.36 | 39.58 | 7.18 | 62.28 | -12.15 |
Other Non Operating Income (Expenses) | 6.23 | 5.35 | 5.54 | 4.46 | 3.59 | 25.69 |
EBT Excluding Unusual Items | 736.9 | 569.4 | 590.96 | 577.86 | 565.23 | 359.5 |
Gain (Loss) on Sale of Assets | -0.6 | -0.52 | 0.31 | 1.07 | 0.57 | 0.11 |
Other Unusual Items | - | - | 1.69 | - | - | 0.04 |
Pretax Income | 736.3 | 568.87 | 592.96 | 578.93 | 565.8 | 359.65 |
Income Tax Expense | 131.66 | 105.09 | 117.27 | 115.64 | 100.37 | 68.15 |
Earnings From Continuing Operations | 604.64 | 463.79 | 475.69 | 463.29 | 465.42 | 291.5 |
Minority Interest in Earnings | 0.06 | 0.21 | 0.7 | - | - | - |
Net Income | 604.7 | 464 | 476.39 | 463.29 | 465.42 | 291.5 |
Net Income to Common | 604.7 | 464 | 476.39 | 463.29 | 465.42 | 291.5 |
Net Income Growth | 65.99% | -2.60% | 2.83% | -0.46% | 59.66% | 191.03% |
Shares Outstanding (Basic) | 103 | 103 | 103 | 97 | 97 | 97 |
Shares Outstanding (Diluted) | 103 | 103 | 103 | 98 | 99 | 98 |
Shares Change | -0.26% | -0.05% | 5.50% | -0.77% | 0.54% | 0.44% |
EPS (Basic) | 5.90 | 4.51 | 4.63 | 4.76 | 4.79 | 3.00 |
EPS (Diluted) | 5.88 | 4.50 | 4.61 | 4.73 | 4.72 | 2.97 |
EPS Growth | 66.63% | -2.39% | -2.54% | 0.21% | 58.92% | 189.44% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 741.37 | 465.68 | -49.98 | 545.47 | 585.08 | 192.43 |
Free Cash Flow Per Share | 7.20 | 4.51 | -0.48 | 5.57 | 5.93 | 1.96 |
Dividend Per Share | 5.300 | 4.800 | 4.100 | 4.090 | 3.880 | 1.304 |
Dividend Growth | 29.27% | 17.07% | 0.24% | 5.41% | 197.48% | 199.98% |
Gross Margin | 84.14% | 83.93% | 83.44% | 83.18% | 79.11% | 83.25% |
Operating Margin | 36.38% | 34.25% | 33.15% | 37.35% | 35.64% | 35.27% |
Profit Margin | 32.27% | 25.51% | 29.12% | 30.58% | 32.45% | 28.62% |
Free Cash Flow Margin | 39.56% | 25.60% | -3.06% | 36.01% | 40.80% | 18.89% |
EBITDA | 871.1 | 807.37 | 704.78 | 703.17 | 628.06 | 435.89 |
EBITDA Margin | 46.48% | 44.38% | 43.09% | 46.42% | 43.79% | 42.80% |
D&A For EBITDA | 189.27 | 184.24 | 162.48 | 137.31 | 117.01 | 76.62 |
EBIT | 681.83 | 623.13 | 542.3 | 565.86 | 511.06 | 359.27 |
EBIT Margin | 36.38% | 34.25% | 33.15% | 37.35% | 35.64% | 35.27% |
Effective Tax Rate | 17.88% | 18.47% | 19.78% | 19.98% | 17.74% | 18.95% |